Pulmonx (LUNG) Q3 2026 Earnings Call Transcript
Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.
How this was made
The 30-second read
Why it matters
The earnings call provides the first public disclosure of Q3 2026 results, showing a return to growth and improved operating leverage, which can shift investor expectations.
Market read
First‑time earnings release with better‑than‑expected growth and margin guidance; likely to move LUNG stock and influence related respiratory‑device peers.
What to watch
China re‑entry may add volatility; trial enrollment timelines could delay revenue upside.
Background
Pulmonx (LUNG) is a U.S. medical‑device company focused on endobronchial valves for COPD and lung volume reduction.
Ticker impact
Pulmonx reported Q3 2026 revenue of $22.8M, a 6% YoY increase and raised full‑year margin guidance to ~77%, indicating a turnaround.
likely upside as investors price in revenue growth and higher margins
First‑time disclosure of quarterly results with better-than‑expected growth and margin expansion; market typically reacts positively to such earnings surprises.
Market effects
Positive signal for the medical device/respiratory therapy sector, may lift peers.
U.S. healthcare stocks could see modest gains.
Limited to niche respiratory‑device market; no broad macro effect.
Counterpoint
Margin guidance still modest; execution risk remains if international expansion stalls.
Key entities
- ExecutiveGlendon E. French
CEO of Pulmonx, presented the earnings call.
- ExecutiveDerrick Sung
CFO/COO, detailed financial results.
